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ABSTRACT: Real-time label-free techniques are used to profile G protein-coupled receptor (GPCR)
signaling pathways in living cells. However, interpreting the label-free signal responses is challenging, and
previously reported methods do not reliably separate pathways from each other. In this study, a continuous
angular-scanning surface plasmon resonance (SPR) technique is utilized for measuring label-free GPCR
signal profiles. We show how the continuous angular-scanning ability, measuring up to nine real-time label-
free parameters simultaneously, results in more information-rich label-free signal profiles for different
GPCR pathways, providing a more accurate pathway separation. For this, we measured real-time full-
angular SPR response curves for Gs, Gq, and Gi signaling pathways in living cells. By selecting two of the
most prominent label-free parameters: the full SPR curve angular and intensity shifts, we present how this
analysis approach can separate each of the three signaling pathways in a straightforward single-step analysis
setup, without concurrent use of signal inhibitors or other response modulating compounds.
G protein-coupled receptors (GPCRs) are the largestfamily of transmembrane proteins. They are responsible
for a number of physiological functions and, as such, play a
crucial role in several diseases. Their importance is highlighted
by the fact that 35% of all FDA approved drugs mediate their
effect via GPCRs,1 and they are still widely investigated for
new drug targets as there are still hundreds of known receptors
that are not targeted by any currently marketed drugs.2 GPCRs
are coupled to heterotrimeric G proteins comprised by Gα,
Gβ, and Gγ subunits, transducing extracellular stimuli into
intracellular signals by promoting the exchange of Gα bound
GDP with GTP, which, in turn, results in subunit dissociation
and second messenger signaling cascades within cells. GPCRs
are divided into four subclasses: Gi/o, Gq/11, Gs, and G12/13,
each interacting uniquely with second messengers, resulting in
receptor-type specific cellular responses. Up- or down-
regulation of functional molecules, specific for each signaling
cascade, causes spatial and temporal events that lead to
ordered and dynamic redistribution of intracellular contents.
Functional biochemical and cell-based assays are widely used
in GPCR research. In addition to detecting ligand binding,
they can also be used to investigate the ligand efficacy to
induce cell signaling and biased signaling.3 Functional assays
detect the presence of second messengers or other downstream
molecules in response to receptor activation.4 As different
receptor subtypes regulate these events in a subtype-specific
manner,5 any given assay detects signaling events only when
signaling occurs via the pathway toward which the assay is
sensitive. Also, even though some assays can be designed to be
sensitive toward multiple pathways, for example, by creating
artificial signaling pathways in cells, these modifications can
alter receptor function.6 Many assays also provide only end-
point data or require addition of labeling compounds, or both.4
Recently, real-time label-free techniques have emerged as
noninvasive alternatives for GPCR signaling pathway detection
in cells.7−10 By immobilizing living cells on sensor surfaces, the
measured label-free signals originate from intracellular changes
in close proximity to the sensor surface as a response to
receptor activation.11 The advantages of real-time label-free
methods are that they provide real-time data and they do not
require labels, which can alter cell functions12 or affect sample
properties,13 to produce a signal output. Also, receptors can be
monitored in their native state without altering their
functionality. Real-time label-free cell assays are, therefore,
excellent for probing new drug candidates as they are not
biased to any GPCR subclass. Common methods used in real-
time label-free cell measurements include electrical impedance
and optical methods such as biolayer interferometry, resonant
waveguide grating (RWG), and surface plasmon resonance
(SPR).7−10,14,15 RWG and SPR function by measuring
refractive index (RI) changes within the evanescent field,
usually reaching a distance of 100−400 nm from the sensor
surface. In practice, RI changes are governed by mass
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alterations and, when cells are immobilized on the sensors, the
RI is dominated by the immense amount of cellular mass16 and
redistribution of intracellular contents upon receptor activa-
tion.8,17
Many GPCR subtypes induce cell responses that are
detectable by label-free techniques, and the spatial and
temporal events occurring within cells translate to character-
istic real-time label-free signal profiles for different GPCR
subtypes.14,15,18 So far, there is convincing evidence that the Gs
pathway can be distinguished from other pathways by simply
observing the real-time label-free responses of agonist-
stimulated cells.7,14,19,20 Attempts have been made toward
also separating the Gq, Gi, and G12/13 pathways, but the results
have not been conclusive.9,10,14,15,18,21,22 Even though real-time
label-free systems have shown their potential as the “swiss
army knife” method for detecting responses initiated by any of
the G protein-coupled pathways mediated by different GPCRs,
they have not yet been successful in correlating the label-free
signal output to specific receptor subtype in a simple single-
step analysis setup. Instead, a multiple-step analysis with
additional antagonists or other response modifying agents have
to be used to associate label-free signal responses to a specific
G protein-coupled signaling cascade.10,21−24 This can be
problematic if antagonists do not exist for a receptor and
especially problematic for orphan receptors with no known
ligands. Lastly, treating cells to silence or otherwise alter G
protein coupling may redirect signaling pathways from their
original activity to alternative cascades.25
In this study, we show that more information-rich real-time
label-free signal profiles for different GPCR signaling pathways
can be derived from the analysis of signal responses obtained
using a continuous angular-scanning SPR method. The
measurements are conducted in a single-step analysis setup
without the need for prior cell treatments, use of antagonists,
or pathway-modulating compounds. Different cell lines
expressing GPCRs coupled to Gαs, Gαi, or Gαq were used as
model systems. Following the agonist-induced receptor
stimulation, we show that the single-parameter SPR signal
profiles for Gs and Gq pathways correlate well with those from
previous studies using similar label-free methods. We then
present how GPCR pathway analysis comparing multiple SPR
parameters provides label-free signal profiles that exhibit
improved specificity to the GPCR signaling via Gq-, Gs-, and
Gi-coupled pathways.
■ MATERIALS AND METHODS
Cell Immobilization on Sensors. Cells were immobilized
on the sensors, as described previously.16 Briefly, cells were
first detached from 80−90% confluent cell culture vessels using
TrypLE Express (12604, Thermo Fisher) or 0.05% trypsin-
ethylenediaminetetraacetic acid (EDTA) (15400, Thermo
Fisher) and resuspended into a complete growth medium at
the desired concentration. Cell suspensions were then carefully
pipetted over the sensors. For HeLa cells, sensors were first
coated with human fibronectin (FC010, Sigma-Aldrich),
whereas for CHO-K1 and A431 cells, uncoated sensors were
used. Sensors with cells were cultured at 37 °C in 5% CO2 for
48−96 h until ∼100% confluent. The culture medium was
renewed once after 24 h of incubation.
Surface Plasmon Resonance (SPR) Measurements.
The SPR experiments were performed using an MP-SPR Navi
instrument (Bionavis Ltd.). Prior to the SPR experiments, flow
channels and all fluidic paths were primed with the assay
buffer, and the flow channels were heated to 37 °C (±0.1 °C).
The used buffer was chosen according to the basal media used
for cell cultures. For CHO-K1 cells, Dulbecco’s modified
Eagle’s medium (DMEM)/nutrient mixture F-12 Ham
containing 15 mM N-(2-hydroxyethyl)piperazine-N′-ethane-
sulfonic acid (HEPES) supplemented with 1% penicillin−
streptomycin (PS) was used. For A431 and HeLa cells, DMEM
containing 1 g/L D-glucose and 25 mM HEPES supplemented
with 1% PS was used. Before inserting the sensors into the SPR
device, the sensors on which the cells were cultured were
examined under a light microscope to confirm sufficient cell
confluence, morphology, and monolayer integrity. A flow rate
of 20−30 μL/min was used and an angle range of 59−76° was
scanned continuously with a temporal resolution of approx-
imately 6.5 s. Once the signal reached a stable baseline,
samples were injected for 15 min, after which buffer flow
resumed. A reference sample with matching composition but
without active compounds was always injected to the second
channel concurrently with the test sample. At the end of the
experiments, cell sensors were treated with trypan blue and
observed under a microscope for viability.
Resonant Waveguide Grating (RWG) Measurements.
RWG measurements were performed using an EnSpire
multimode reader (PerkinElmer). Before experiments, media
in the well plates were replaced with the assay buffer. The plate
was then inserted into the device and equilibrated for 1 h, after
which a baseline read was taken for 30 min. Next, samples were
introduced to cells by ejecting the plate and pipetting sample
solutions to the wells. Three wells were used as controls, where
only buffer was added. The plate was then inserted quickly
back into the device and real-time measurement was started.
The wavelength shifts in all of the wells from one quarter of a
96-well plate were detected simultaneously. The maximum
temporal resolution of 15 s was used. Experiments were
performed at 26 °C (±3 °C). Assay buffer was DMEM
containing 4.5 g/L D-glucose supplemented with 1% PS and 10
mM HEPES. All samples were measured in three replicates.
Data Analysis. SPR data were extracted using the SPR
Navi Data viewer software (v. 4.3.3) (Bionavis Ltd.). The
moment of sample injection was selected as a zero time point,
where time and SPR response were set as zero. Further data
analysis was done using OriginPro (v. b9.5.5.409) (OriginLab
Corporation, Northampton, MA) and GraphPad Prism (v.
8.4.1) (GraphPad Software, San Diego, CA). All real-time cell
responses were background corrected by subtracting any bulk
response caused by the reference sample in the control channel
from the response of the sample channel. The area under the
curve (AUC) was used to plot concentration-response curves
from which EC50 values were determined using nonlinear
regression. AUC was calculated from T0 to Tend, where T0 is
defined as the moment immediately before the sample enters
the measurement channel and Tend is the SPR signal at the
time when sample injection is ended. Any negative values were
neglected when calculating AUC values.
RWG data were extracted using EnSpire Manager software
(v. 4.1) (PerkinElmer). All data analysis was done using
OriginPro and GraphPad Prism. The average response of three
control wells was subtracted from the sample well responses
and real-time data were plotted as picometers (pm) against
time.
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■ RESULTS
The cell lines used in this study express different GPCRs,
which are coupled to three different G proteins: Gi, Gq, and Gs,
each initiating their respective cell signaling pathways. With
A431 cells, the agonists used were bradykinin and epinephrine,
which bind to bradykinin B2 and ß2-adrenoceptors, activating
Gq and Gs pathways, respectively. With HeLa and CHO-K1
cells expressing the histamine H3 receptor hH3R-445 (CHO-
K1-hH3R), histamine was used, which binds to histamine H1
and H3 receptors, activating Gq and Gi pathways in these cells,
respectively. The other ligands and their targets used in this
study are shown in Table 1.
Cell Immobilization on Sensors. All cell lines were
successfully immobilized on the SPR sensors and showed near
fully confluent cell monolayers under the microscope at the
end of the incubation periods. CHO-K1 and A431 cells
attached to the gold-coated sensors and retained uniform
monolayers and cell viability, even after an extended time in
the SPR instrument during the experiments (Figure S1A,B),
whereas Hela cells remained fully attached on sensors only
when a fibronectin coating was applied (Figure S1C,D).
The presence of cell monolayers was also evident from the
full SPR curves (Figure S2). The SPR sensors without cells
show a sharp and definable total internal reflection (TIR)
region at an angle around 61°, and the position of the main
SPR peak or peak angular position (PAP) at an angle around
66°. Noticeable changes in TIR and PAP were observed with
the cell monolayers present on the sensors. The exact shape
and the position of the TIR region and the PAP were
somewhat dependent on the cell type. In general, cells caused
the TIR region to become less defined with an angular position
at around 63°, while the PAP increased to 68−69°.
SPR Peak Angular Position (PAP) Responses During
GPCR Activation. Figure 1 shows the SPR PAP responses
against time during the stimulation of A431 cells with different
concentrations of epinephrine and bradykinin, and during the
stimulation of CHO-K1-hH3R and HeLa cells with different
concentrations of histamine. All agonists caused immediate
responses in PAP. A431 cells with bradykinin and epinephrine
showed unique real-time signal profiles: bradykinin caused a
rapid signal increase, reaching a maximal signal shift close to
600 millidegrees within 2 min with the three highest
concentrations, after which the signals started to quickly
decrease, reaching close to the initial values during the 15 min
sample injections (Figure 1A). Epinephrine, on the contrary,






bradykinin agonist bradykinin B2 (Gq) A431
epinephrine agonist ß2-adrenoceptor (Gs) A431





mepyramine antagonist histamine H1 (Gq) HeLa,
CHO-K1-hH3R
ranitidine antagonist histamine H2 HeLa,
CHO-K1-hH3R
thioperamide antagonist histamine H3 (Gi)/H4 HeLa,
CHO-K1-hH3R
JNJ-7777120 antagonist histamine H4 HeLa,
CHO-K1-hH3R
aA431 = human epithelial squamous carcinoma cell line, HeLa =
human epithelial cervical adenocarcinoma cell line, CHO-K1 =
PathHunter Chinese hamster ovary (CHO-K1) parental cell line, and
CHO-K1-hH3R = CHO-K1 cell line expressing the hH3R-445.
Figure 1. Representative surface plasmon resonance (SPR) peak angular position (PAP) responses to G protein-coupled receptor activation.
Responses to different concentrations of bradykinin (A) and epinephrine (B) with A431 cells and to different concentrations of histamine with
CHO-K1-hH3R cells (C) and HeLa cells (D).
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caused a small initial decrease in the PAP response (Figure
1B). However, this was reversed within 60−90 s, after which
the response showed a two-phased signal increase: a rapid rise
lasting 2−4 min and a slower rise until the end of the sample
injection, reaching a maximal signal shift of around 180
millidegrees at 1 μM. Histamine with CHO-K1-hH3R cells
showed very similar PAP response patterns compared to
bradykinin with A431 cells: an immediate signal increase,
followed by a gradual decrease after reaching a maximal signal
shift of around 300 millidegrees with the three highest
concentrations (Figure 1C). Histamine with HeLa cells
showed PAP response characteristics from both bradykinin
and epinephrine with A431 cells: the signal increased
immediately, reaching a maximum shift of 520 millidegrees
at 100 μM and showing only slight or no signal decrease
during sample injections (Figure 1D). The PAP response
curves were used to calculate the AUC values, whereby
concentration-response curves were plotted and the EC50
values were subsequently calculated for all agonists (Figure
S3). Average pEC50 values (±standard error of mean (SEM))
of 8.0 ± 0.09 (n = 3) for bradykinin and 8.9 ± 0.13 (n = 3) for
epinephrine were obtained, while the pEC50 values (±SEM)
for histamine with CHO-K1-hH3R cells was 6.9 ± 0.29 (n = 3)
and 5.7 ± 0.06 (n = 3) with HeLa cells.
To observe cell responses to ligand removal, SPR measure-
ments were allowed to continue after sample injections ended.
With all agonists, PAP signals returned to their initial values, or
very close to the initial values (data not shown). Also, the cells
remained responsive to repeated stimulation with the same
ligand, except with the HeLa cells, where a second histamine
stimulation showed a clearly desensitized response even after
135 min washout between the sample injections (Figure S4).
Pathway Analysis. In addition to PAP, continuous
recording of the full SPR curve allows monitoring of several
other SPR signal responses (Figure 2A). We plotted eight
additional SPR parameters: peak minimum intensity (PMI),
peak amplitude, peak width at 0.25 intensity, peak width at
0.25 peak amplitude, TIR angle, TIR intensity, steepest fall
intensity, and steepest fall angle for all agonists at
concentrations above their EC50 values (Figure 2B−J). Many
of these signal responses exhibited consistent and pathway-
dependent changes. To further evaluate these additional
parameters, rather than observing them one by one, we
plotted all of the additional parameters against PAP responses
(Figure S5). Four of these plots showed potential for pathway
separation. However, the PMI against PAP exhibited
particularly promising pathway specificity and was, therefore,
chosen for further analysis (parameters B and C from Figure
2). PMI is the measure of the dynamic intensity shift of the
peak minimum of the full SPR curve (Figure 2A). Figure 2B
shows a comparison of representative PMI responses for all
agonists. The observed PMI signals can be divided into two
distinct response profiles: increasing or decreasing below the
baseline. Histamine with HeLa cells and bradykinin with A431
cells show an increase in PMI responses, while histamine with
CHO-K1-hH3R cells and epinephrine with A431 cells show a
decrease in PMI. The PMI profile for bradykinin closely
resembles the bradykinin PAP profile: signal reaches its peak
maximum in less than 60 s and then exhibits a quick return to
initial baseline (compare Figure 2B and Figure 2C). Histamine
PMI response with HeLa cells resembles the bradykinin PMI
response profile, except that the signal shows slightly slower
kinetics, reaching the peak after 2 min and declining back to
the initial value only toward the end of sample injection.
Histamine with CHO-K1-hH3R cells and epinephrine with
A431 cells both show similar PMI response profiles, with only
a decline in the signal, reaching the minimum within 5−6 min.
However, the decrease in PMI response for epinephrine with
A431 cells was negligible compared to histamine with CHO-
K1-hH3R cells and, therefore, not visible in Figure 2B. The
PMI response peaks for histamine with HeLa and CHO-K1-
hH3R cells reached maximum and minimum PMI shifts of
0.045 and −0.073, respectively. Bradykinin and epinephrine
showed much subtler responses with maximum and minimum
PMI shifts of 0.025 and −0.0014, respectively.
Figure 3 shows the two-parameter PMI-PAP response
profiles for all agonists with all cell lines at agonist
concentrations that induce maximum signal responses. From
this graph, it is clear that each GPCR signaling pathway
produces an unambiguously distinguishable pattern on this
two-dimensional angle-intensity graph. Both compounds
activating Gq-coupled receptors in different cellular contexts,
Figure 2. Representative real-time responses of additional surface plasmon resonance (SPR) parameters. (A) Representation on how different SPR
parameters relate to the measured full SPR curve. (B−J) Real-time responses of peak minimum intensity (B), peak angular position (C), peak
width at 0.25 intensity (D), peak width at 0.25 peak amplitude (E), steepest fall angle (F), steepest fall intensity (G), total internal reflection (TIR)
intensity (H), TIR angle (I), and peak amplitude (J) during sample injections of histamine with HeLa cells (orange dashed lines), bradykinin with
A431 cells (blue dotted lines), epinephrine with A431 cells (red solid lines), and histamine with CHO-K1-hH3R cells (green dashed and dotted
lines). All signal response curves are for agonists at concentrations well above their EC50 values.
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lean to the right and create a loop shape. The Gi-coupled
receptor activation creates a similar loop but leans strongly to
the left, while the Gs-coupled receptor activation draws a
straight line across the y-axis.
SPR Responses Originate from Receptor Activation.
To confirm that the measured SPR signals originate from the
cell responses specific to GPCRs, we used a range of histamine
receptor antagonists, G protein inhibitors, and parental CHO-
K1 cells that were not transfected with the hH3R-445. As
expected, parental CHO-K1 cells did not show any response
when exposed to 300 nM histamine (Figure S6A). Histamine
H1 receptor antagonist mepyramine at 1 μM, histamine H2
receptor antagonist ranitidine at 10 μM, or histamine H4
receptor antagonist JNJ-7777120 (JNJ) at 1 μM did not
attenuate CHO-K1-hH3R cell responses to 300 nM histamine
(Figure S6B). On the contrary, thioperamide, an H3/H4
antagonist at 1 μM, given concurrently with 300 nM histamine,
decreased the PAP AUC to around 10%, compared to
histamine alone. Furthermore, overnight treatment with 1
μM YM-254890 (YM), a peptide inhibiting Gq-coupled
receptor signaling, did not inhibit cell response to histamine,
whereas overnight treatment with 100 ng/mL pertussis toxin
(PTX), a Gi inhibitor, completely abolished the response. With
HeLa cells, which endogenously express Gq-coupled histamine
H1 receptors, no effect was seen when cells were stimulated
with 10 μM histamine concurrently with 10 μM ranitidine, 1
μM thioperamide, and 1 μM JNJ or after cells were treated
overnight with 100 ng/mL PTX (Figure S6C). However, with
concurrent exposure to 1 μM mepyramine, the PAP AUC
decreased to around 7% of that with histamine alone and to
around 6% after 15 min treatment with 10 μM YM.
Comparison of SPR PAP Responses with RWG
Responses. We compared the SPR PAP responses with
responses measured using RWG. Results from both systems
were well in accordance with each other (Figures 4A and S7).
The overall shapes of the RWG and SPR response curves
follow closely similar patterns. However, with bradykinin-
stimulated A431 cells, the main response peaks in RWG always
occurred at earlier time points and saturated at lower agonist
concentrations compared to SPR. This is more pronounced
with the highest concentration, where the initial signal shift is
rapid and strong (Figure 4A). These differences are most likely
a consequence of sample handling. With RWG, measurement
is halted during sample addition and initial cell response is
therefore lost, whereas with SPR, measurement is never
interrupted.
Despite these differences, the concentration-response curves
plotted for RWG and SPR responses compare closely with
each other (Figure 4B). The EC50 value for bradykinin-
stimulated A431 cells calculated from AUC of the RWG
responses was around 3 nM, which is close to the value of 10
nM obtained using the SPR responses. The slightly lower EC50
value with RWG is probably a consequence of the loss of initial
temporal resolution.
■ DISCUSSION
The sensitivity of real-time label-free methods allows detecting
very small mass alterations originating from localized cellular
mass rearrangement, such as changes in cell morphology or
even intracellular mass movements.26 This mass sensing
property makes real-time label-free cell assays inherently
different from traditional functional cell assays, as all cell
events occurring within the detection area are monitored
instead of only a single specific predetermined cellular
Figure 3. Two-parameter surface plasmon resonance (SPR) response
profiles. Peak angular position (PAP) responses are plotted against
peak minimum intensity (PMI) responses for histamine with CHO-
K1-hH3R cells (green lines with dashes and dots, Gi), epinephrine
with A431 cells (red solid lines, Gs), bradykinin with A431 cells (blue
lines with dots, Gq), and histamine with HeLa cells (orange lines with
dashes, Gq). For each response profile, three independent measure-
ments with agonists at concentrations inducing maximum PAP
responses are shown.
Figure 4. Comparison between surface plasmon resonance (SPR) and
resonant waveguide grating (RWG). (A) Representative real-time
responses to different concentrations of bradykinin with A431 cells on
sensors. Concentrations are: 1, 5, 10, and 500 nM with orange solid
lines, blue dashed lines, green dotted lines, and red dashed and dotted
lines, respectively. Lines without markers are SPR responses and lines
with markers are RWG responses. Left y-axis is SPR PAP response
and right y-axis RWG response. (B) Representative concentration-
response curves for bradykinin determined from the area under the
curve (AUC) of SPR PAP and RWG responses. RWG responses are
the solid blue line with circles and SPR PAP responses are the dashed
red line with squares.
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response. This makes these methods a great choice for
measuring a number of different cell responses, such as GPCR
cell signaling. GPCR pathway analysis with label-free methods
is based on the ability of these techniques to translate the
spatial and temporal mass redistribution within cells into real-
time signals.9,14,15 As the activated GPCR signaling pathways
within cells can lead to either an increase or decrease in relative
mass within the label-free sensing area, the label-free responses
can also exhibit either a signal increase or decrease from their
baseline level, respectively. So far, the label-free identification
of Gs and Gq pathways by previous studies have been owed
mainly to the uniqueness of the Gs response profile, specifically
the initial negative peak but also to the analysis of the time-
response signal profile as a whole.19,27 This time-resolved
pathway recognition may work when separating GPCR
signaling within the same cellular context, but the same
signaling pathways that are activated in different cell types can
produce quite different label-free response profiles (compare
Figure 1A and Figure 1D).28 Also, it is interesting to note that
much of the data interpretation so far has been focused only on
differentiating Gs response from other pathways and on general
profiling of Gq and Gi time-response signals. This might be
simply due to the time-resolved signal profiles not being
sufficiently distinctive to separate Gq and Gi signaling from
each other.10,14,15,29 Furthermore, even though impedance-
based methods have shown some potential in distinguishing
between these three G protein signaling pathways, the analysis
still relies on subtle differences in the kinetic profile of only a
single parameter18 or two closely related parameters.30
Moreover, results have been variable, where in some cases,
depending on the type of instrument and cell lines used, the
responses for the same pathway have shown very different
response patterns.9,15,18 To circumvent these drawbacks, an
alternative approach, applied in many label-free studies, is to
introduce compounds, such as antagonists or inhibitors
targeting the signaling proteins, in addition to the agonists to
alter or silence label-free responses to separate GPCR signaling
pathways.10,21 However, this introduces more complexity in
label-free assays. Because of these challenges, there has not
been a well-established label-free method to distinctively
distinguish between these three GPCR signaling pathways in
a straightforward manner.
Like with other label-free systems, the SPR PAP signals
presented in this study reflect the subtle mass redistribution
taking place in cells during GPCR activation. In RWG
measurements, this is often referred to as dynamic mass
redistribution (DMR). However, with the angular-scanning
SPR, we are not limited only to measuring the PAP responses.
Instead, much more information-rich label-free signals can be
extracted from the full SPR curves (Figure 2A). While it has
been demonstrated that more than one parameter can also be
measured with angular-scanning RWG,17 further pathway
analysis using additional parameters has not been explored.
We have previously demonstrated how the continuously
recorded full SPR curve can provide deeper label-free analysis
of cellular responses.31 Measuring the dynamic responses of
the full SPR curves during the activation of GPCRs revealed
that, in addition to PAP, at least five other label-free
parameters exhibited time-dependent responses that might be
used for pathway separation (Figure 2B,D,E,I,J). Of these,
further analysis indicated that the PMI signals showed the best
separation of GPCR subtypes (Figures 3 and S5). Unlike the
PAP responses, the PMI signals are not sensitive directly to the
amount of mass within the evanescent field. Instead, PMI is
affected by the amount of light that is reflected back at the SPR
coupling angle and is sensitive to any absorbing or scattering
surfaces within the sensing depth. With cell assays, this means
that any event where the total mass does not necessarily
change, but the surface area of scattering interfaces that the
surface plasmons encounter increases or decreases, changes in
PMI occur. This type of scatter-inducing changes in cells have
been described earlier and were associated mainly with
morphological changes in the cell membrane.32 Of course,
other cellular processes can be expected to also influence
surface plasmon scattering.
When looking at the PMI changes caused by the activation
of different GPCRs, it is evident that, like the PAP responses
presented here and other label-free signal profiles reported by
other groups, the PMI responses also display complex kinetic
profiles, indicating that PMI responses are sensitive to the
unique cellular processes initiated by different active G protein
subtypes. What is more interesting, compared to the PAP
profiles, is that the SPR PMI responses seem to exhibit higher
signal pattern specificity for each pathway: increase, decrease,
and only a minor negative change in PMI responses for Gq, Gi,
and Gs pathways, respectively (Figure 2B). Also, it seems that
the PMI responses are not as sensitive to the cellular context as
PAP responses, as evident from the more apparent correlation
of the PMI profiles associated to the Gq signaling pathway,
demonstrated by bradykinin-stimulated A431 cells and
histamine-stimulated HeLa cells (compare Figure 2B and
Figure 2C). Because of these unique PMI responses, the three
GPCR signaling pathways are, in this case, recognizable solely
from the PMI profiles. However, by observing PAP and PMI
together, stronger correlation between SPR response patterns
and GPCR signaling pathways, especially across different
cellular backgrounds, should be achieved (Figure 3). However,
further experiments, collecting data from broader selection of
cell lines, receptor types, and a range of different ligands
targeting these receptors, are warranted to validate the
robustness of this multiple SPR parameter analysis as a
method for unambiguous GPCR pathway recognition. Also,
the cellular context for measuring the G12/13 pathway with
angular-scanning SPR should be investigated to establish the
label-free signal profile for this pathway.
Because SPR has not been widely used for GPCR signal
profiling, comparison with more established label-free systems
is warranted. The observed PAP time-response profiles for Gq
and Gs signaling pathways are in good accordance with the
results from other groups using similar optical label-free
systems: activation of the Gq signaling pathway in A431 cells
shows a two-phased overall response profile with a rapid initial
signal increase followed by a decreasing signal (Figure 1A),14
while the same pathway in HeLa cells shows only an increasing
overall signal profile with little or no signal decrease (Figure
1D).8,28 In addition to differences in the Gq response profiles
under a different cellular context, some Gq signal profile
differences in the same cell type can also be observed between
different studies: Lu et al.8 reported a triphasic early Gq signal
increase with HeLa cells using both SPR and impedance
methods, while results by Yu et al.15 using an impedance
method and by Deng et al.28 using RWG showed, similarly to
our results, only a single-phased early signal increase. For the
Gs pathway, the signal profiles seem to be fairly uniform even
across different label-free techniques and cell types.7,9,14 To the
best of our knowledge, real-time label-free Gs signaling
Analytical Chemistry pubs.acs.org/ac Article
https://dx.doi.org/10.1021/acs.analchem.0c02652
Anal. Chem. 2020, 92, 14509−14516
14514
pathway responses are not previously reported using SPR. Our
results show that the SPR responses during Gs activation are
very well in line with other label-free methods, showing an
immediate but transient signal decrease followed by a two-
phased increase (Figure 1B). There have been previous
attempts to also profile the Gi signaling pathway using RWG
and impedance methods, and even though results have not
been conclusive, all cell responses attributed to the Gi signaling
pathway have shown signal profiles with increasing signal
responses,9,10,14,15,18,21,22,29 and our results support these
previous observations (Figure 1C). Lastly, the EC50 values
obtained for histamine with HeLa cells and for epinephrine
and bradykinin with A431 cells are well in line with previously
reported values measured with optical label-free methods.8,27,33
However, it is worth noting that the EC50 value for histamine
with CHO-K1-hH3R cells shows greater variation than the
other agonist-receptor pairs (Figure S3C). This is likely due to
loss of receptor expression with cells having higher passage
numbers, resulting in lowered SPR responses (Figure S8).
We also compared the SPR technique directly with RWG.
Parallel measurements showed that the SPR and RWG
responses correlated closely. PAP responses from SPR and
RWG responses showed matching Gq and Gs signal profiles
with A431 cells and comparable EC50 values for bradykinin
(Figures 4 and S7). An advantage of SPR over RWG is that
information on receptor activation is obtained in dynamic flow
conditions with no delay in measured responses. This was
observed as better SPR sensitivity to higher bradykinin
concentrations with A431 cells (Figure 4).
The observations presented in this study, and results
reported in previous studies by other groups, indicate that
while the label-free signal profiles depend mainly on the GPCR
signaling pathway, they are also dependent on the cellular
context and the label-free techniques used as these methods
are sensitive to a variety of assay conditions. Therefore, other
factors besides GPCR signaling pathways can play an
important role in the observed label-free signal responses
and, therefore, using the time-resolved single-parameter signal
profile analysis alone for interpreting GPCR signaling pathways
presents some uncertainty. This underlies the need for more
advanced signal analysis methods for an unambiguous GPCR
pathway recognition by real-time label-free methods, such as
using multiple label-free parameters concurrently.
■ CONCLUSIONS
We have demonstrated how the continuous angular-scanning
SPR can be used to recognize and separate GPCRs into
subtype-specific Gq, Gs, and Gi signaling pathways. Label-free
detection occurs in real-time and pathway separation is
achieved by measuring multiple SPR parameters during cell
exposure to receptor agonists only. No concurrent antagonists
or other response modulating agents are required. We
measured the signaling profiles for the Gq and Gi pathways
and, to our knowledge, for the first time with SPR for the Gs
pathway. We showed that by combining different label-free
parameters (in this study the dynamic angular (PAP) and
intensity (PMI) shifts of the full SPR curve peaks), each
subtype-specific GPCR signaling pathway creates a unique
label-free response profile, from which GPCR signaling routes
can be identified. To date, the focus in label-free GPCR
profiling has remained on signal deconvolution in the presence
of response modulating compounds and high-throughput
analysis. We believe that the results presented in this study
demonstrate that the strength of real-time label-free methods
lies in fact in the high information content that these
techniques are capable of and, therefore, need for more
advanced signal analysis methods is justified.
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Imhof, D.; Aoki, J.; König, G. M.; Hoffmann, C.; Gomeza, J.; Wess, J.;
Kostenis, E. Nat. Commun. 2018, 9, No. 341.
(30) Leung, G.; Tang, H. R.; McGuinness, R.; Verdonk, E.;
Michelotti, J. M.; Liu, V. F. J. Assoc. Lab. Autom. 2005, 10, 258−269.
(31) Viitala, T.; Granqvist, N.; Hallila, S.; Raviña, M.; Yliperttula, M.
PLoS One 2013, 8, No. e72192.
(32) Yashunsky, V.; Lirtsman, V.; Golosovsky, M.; Davidov, D.;
Aroeti, B. Biophys. J. 2010, 99, 4028−4036.
(33) Li, G.; Ferrie, A. M.; Fang, Y. J. Assoc. Lab. Autom. 2006, 11,
181−187.
Analytical Chemistry pubs.acs.org/ac Article
https://dx.doi.org/10.1021/acs.analchem.0c02652
Anal. Chem. 2020, 92, 14509−14516
14516
